https://www.indianpharmapost.com/indraprastha-medical-corporation-posts-q4-fy25-pat-at-rs-4101-cr-171642025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/solara-active-pharma-sciences-posts-q4-fy25-consolidated-loss-at-rs-210-cr-171742025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/wanbury-posts-q4-fy25-consolidated-pat-at-rs-2025-cr-171732025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/abbott-india-posts-q4-fy25-net-profit-at-rs-36704-cr-171722025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/alembic-pharmaceuticals-receives-usfda-final-approval-for-rivaroxaban-tablets-usp-171712025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/lupin-receives-usfda-approval-for-rivaroxaban-tablets-171702025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/punita-lal-joins-lupin-board-as-additional-director-171692025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/sun-pharma-gets-fda-approval-for-new-device-to-treat-skin-disease-171682025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/briefs-dr-reddys-laboratories-relonchem-shilpa-pharma-lifesciences-and-shanmuga-hospital-171672025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/hikal-posts-q4-fy25-consolidated-pat-at-rs-50-cr-171662025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/alivus-life-sciences-reports-q4-fy25-pat-at-rs-14186-cr-171652025-05-18T00:00:00+05:30always0.9https://www.indianpharmapost.com/neuland-laboratories-posts-q4-fy25-consolidated-pat-at-rs-2780-cr-171752025-05-18T00:00:00+05:30always0.9